in partnership with the World Health Organization (WHO)
Event
Session Type
Conference
Room number
Room XXV
Contact Email
christoph.spennemann@unctad.org
23 October 2018
14:30 - 17:30 Europe/Zurich
Europe/Zurich
Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment. It will present some innovative technologies that need financial support and provide a matchmaking platform to connect impact investors with researchers and developers of treatments against AMR.
Issues for the debate
- What is the role of governments?
- What are the needs of the industry?
- Which innovative means of investment can help address the AMR problem?
Speaker(s)
Chief Scientific Officer for Infectious Diseases Pharmaceutical Research Division SHIONOGI & CO., LTD.
Head of Scientific Affairs, Global Antibiotic Research and Development Partnership (GARDP)
Policy Advisor, ReAct - Action on Antibiotic Resistance Uppsala University, Sweden
Director-General, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austria
Executive Manager of Strategic Research Initiatives, South Africa Medical Research Council
Expert Advisory Board Chair, United Kingdom Global AMR Innovation Fund
Deputy Secretary-General, United Nations Conference on Trade and Development
